Recombinant measles AIK-C vaccine strain expressing heterologous virus antigens
Related Experiment Video
Updated: Mar 30, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Tetsuo Nakayama1, Akihito Sawada1, Yoshiaki Yamaji1
1Kitasato Institute for Life Sciences, Laboratory of Viral Infection I, Minato-ku, Tokyo 108-8641, Japan.
Abstract:
Further attenuated measles vaccines were developed more than 50 years ago and have been used throughout the world. Recombinant measles vaccine candidates have been developed and express several heterologous virus protective antigens. Immunogenicity and protective actions were confirmed using experimental animals: transgenic mice, cotton rats, and primates. The recent development of measles vaccine-based vectored vaccine candidates has been reviewed and some information on recombinant measles vaccines expressing respiratory syncytial virus proteins has been shown and discussed.
More Related Videos
13:36Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
10:39Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Published on: June 25, 2015
Related Concept Videos
00:57Viral Recombination
00:42Cross-reactivity